8-K filing — Cocrystal Pharma, Inc. (COCP)
Filed: 2026-09-09 AccNo: 0001493152-26-041877 Size: 223 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Cocrystal Pharma Secures $5M Investment From OPKO Health To Advance Norovirus Program Toward Phase 1b Data
Longtime investor OPKO Health increases its position as Cocrystal advances toward norovirus Phase 1b data in late 2026BOTHELL, Wash., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP)
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Cocrystal Pharma Announces Last Subject Dosed In Phase 1b Norovirus Challenge Study Of CDI-988; Says No Serious Adverse Events To Date, Preliminary Efficacy Results Expected Late 2026 Or Early 2027
Cocrystal Pharma Q2 EPS $(0.23) Misses $(0.17) Estimate, Sales $105.000K
Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.17) by 43.75 percent. This is a 15 percent decrease over losses of $(0.20) per share from
Cocrystal Pharma shares are trading higher after the company announced a $5 million private placement with OPKO Health.
8-K filing — OPKO HEALTH, INC. (OPK)
Filed: 2026-10-02 AccNo: 0001193125-26-412284 Size: 148 KB Item 8.01: Other Events
Steris (STE) Down 2.1% Since Last Earnings Report: Can It Rebound?
STERIS reported strong Q1 fiscal 2027 results with adjusted EPS of $2.59 (up 10.7% YoY) beating estimates by 1.97%, driven by higher volume, pricing, and productivity across all segments. However, revenues of $1.49 billion missed consensus by 0.83%. The company reaffirmed its fiscal 2027 guidance for 7-8% revenue growth and $11.10-$11.30 adjusted EPS. Despite solid earnings, shares have underperformed the S&P 500 by 2.1% since the report.